Findings

What do systematic reviews say?

9 questions · 9 findings · 2 reviews · Musculoskeletal

No studies found 1 · 11.1%GRADE not reported 0 · 0%Very low 4 · 44.4%Low 0 · 0%Moderate 1 · 11.1%High 3 · 33.3%

Change in pain (0‐100 mm VAS) · patients with rheumatoid arthritis in adults

1 finding from 1 review

Leflunomide for the treatment of rheumatoid arthritis 2002 · Cochrane Headline outcomes only
no estimate extracted
1 study · 263 participants
High

Withdrawals due to adverse events · patients with rheumatoid arthritis in adults

1 finding from 1 review

Leflunomide for the treatment of rheumatoid arthritis 2002 · Cochrane Headline outcomes only
no estimate extracted
1 study · 263 participants
Moderate

For outcome · patients with rheumatoid arthritis in adults

The review found no eligible studies for this question.

1 finding from 1 review

Leflunomide for the treatment of rheumatoid arthritis 2002 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

ACR 50% improvement · patients with rheumatoid arthritis in adults

Summary of findings: leflunomide + methotrexate leads to higher ACR 50 at 6 months compared with methotrexate, 6 months (high certainty).

1 finding from 1 review

Leflunomide for the treatment of rheumatoid arthritis 2002 · Cochrane Headline outcomes only
RR 4.35 [2.09, 9.03]
1 study · 263 participants
High

HAQ change from baseline Scale from: 0 to 3. · patients with rheumatoid arthritis in adults

1 finding from 1 review

Leflunomide for the treatment of rheumatoid arthritis 2002 · Cochrane Headline outcomes only
no estimate extracted
1 study · 263 participants
High

Serious adverse events (leflunomide) assessed by number of events · psoriatic arthritis

1 finding from 1 review

Methotrexate for psoriatic arthritis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 61 participants
Very low

Withdrawals due to adverse events · psoriatic arthritis

1 finding from 1 review

Methotrexate for psoriatic arthritis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 61 participants
Very low

Disease response (leflunomide) · psoriatic arthritis

It is very uncertain whether methotrexate changes disease response (leflunomide) compared with other DMARDs (very low certainty).

1 finding from 1 review

Methotrexate for psoriatic arthritis 2019 · Cochrane Headline outcomes only
RR 1.05 [0.77, 1.45]
1 study · 30 participants
Very low

Function (leflunomide) · psoriatic arthritis

1 finding from 1 review

Methotrexate for psoriatic arthritis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 31 participants
Very low